Exagen Inc. is a provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision-making. The Company has developed and is commercializing a portfolio of testing products, under its AVISE brand. It commercially launched its testing product, AVISE CTD, which enables differential diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The comprehensive nature of AVISE CTD allows for the testing of various relevant biomarkers in one convenient blood draw. Included in AVISE CTD is its proprietary AVISE Lupus test, which enables the diagnosis of systemic lupus erythematosus (SLE) based on levels of erythrocyte bound C4d (EC4d) and B cell C4d (BC4d); along with anti-nuclear antibodies (ANA) and double-stranded DNA antibodies (ds-DNA). AVISE Lupus provides rheumatologists and their patients with sensitive and specific results.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で22.12%の成長率を示しています。
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 55.64Mに達しています。
割安
同社の最新のPEは-10.27で、過去3年間の水準と比較して安値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は14.11M株で、前四半期比で11.99%減少しています。
バンガードが保有
スター投資家バンガードは本銘柄を681.62K株保有しています。
市場活動が低調
同社への投資家の関心は低下しており、20日間の売買回転率は0.96です。